Prostate Cancer Reports


Volume 3 Supplement 1
January 2015

Home > Prostate Cancer Reports > Volume 3, Year 2015 > Supplement 1, January


CONTENTS



Detection, diagnosis and evaluation
Etiology and pathogenesis
Integrative medicine
Overall management
Prognosis and outcome
Prostate-specific antigen
Quality of life
Treatment



DETECTION, DIAGNOSIS AND EVALUATION



Bratan F, Melodelima C, Souchon R, Dinh AH, Mège-Lechevallier F, Crouzet S, Colombel M, Gelet A, Rouvière O.
How Accurate Is Multiparametric MR Imaging in Evaluation of Prostate Cancer Volume?
Radiology. 2014 Nov 21:140524. [Epub ahead of print]
Abstract | Related citations


Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA.
Local recurrence map to guide target volume delineation after radical prostatectomy.
Pract Radiat Oncol. 2014;4(6):e239-46. doi: 10.1016/j.prro.2014.02.007. Epub 2014 Apr 16.
Abstract | Related citations

ETIOLOGY AND PATHOGENESIS



Stoletov K, Bond D, Hebron K, Raha S, Zijlstra A, Lewis JD.
Metastasis as a therapeutic target in prostate cancer: a conceptual framework.
Am J Clin Exp Urol. 2014 Apr;2(1):45-56.
Abstract | Full text | Related citations

INTEGRATIVE MEDICINE



Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M.
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.
Invest New Drugs. 2014 Nov 29. [Epub ahead of print]
Abstract | Related citations


Küllenberg de Gaudry D, Massing U.
[Importance of long chain omega-3 fatty acids in prostate cancer].
Urologe A. 2014 Nov;53(11):1620-4. doi: 10.1007/s00120-014-3612-3.
Abstract | Related citations

OVERALL MANAGEMENT



Aggarwal RR, Small EJ.
Small-cell/neuroendocrine prostate cancer: a growing threat?
Oncology (Williston Park). 2014 Oct;28(10). pii: 201920.
Abstract | Full text | Related citations


Aparicio A, Tzelepi V.
Neuroendocrine (Small-Cell) Carcinomas: Why They Teach Us Essential Lessons About Prostate Cancer.
Oncology (Williston Park). 2014 Oct 15;28(10). pii: 201919.
Abstract | Full text | Related citations

PROGNOSIS AND OUTCOME



Lee JJ, Thomas IC, Nolley R, Ferrari M, Brooks JD, Leppert JT.
Biologic differences between peripheral and transition zone prostate cancer.
Prostate. 2014 Oct 18. doi: 10.1002/pros.22903. [Epub ahead of print]
Abstract | Related citations


Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K.
Who dies from prostate cancer?
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):348-52. doi: 10.1038/pcan.2014.35. Epub 2014 Oct 14.
Abstract | Related citations


Biochemical recurrence


Cancer-specific mortality


Salvage androgen deprivation therapy following biochemical failure post-salvage radiation therapy


Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA.
Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
Radiat Oncol. 2014 Nov 26;9(1):245. [Epub ahead of print]
Abstract | Full text | Related citations


Positive surgical margins and cancer-specific mortality


Retèl VP, Bouchardy C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G, Iselin C, Miralbell R, Rapiti E.
Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study.
BMC Urol. 2014 Nov 5;14:86. doi: 10.1186/1471-2490-14-86.
Abstract | Full text | Related citations


Positive surgical margins


Watkins JM, Laszewski M, Watkins PL, Dufan TA, Adducci C.
Margin involvement at prostatectomy for clinically localized prostate cancer: Does a low-risk group exist?
Pract Radiat Oncol. 2015 Jan-Feb;5(1):e31-6. doi: 10.1016/j.prro.2014.04.005. Epub 2014 Jun 2.
Abstract | Related citations

PROSTATE-SPECIFIC ANTIGEN



Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK.
Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
Pract Radiat Oncol. 2014;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.
Abstract | Related citations


Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K.
Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: A single-centre experience.
Scand J Urol. 2014 Nov 27:1-6. [Epub ahead of print]
Abstract | Full text | Related citations


Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES.
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Prostate Cancer Prostatic Dis. 2014 Nov 11. doi: 10.1038/pcan.2014.44. [Epub ahead of print]
Abstract | Related citations

QUALITY OF LIFE



Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA, Leventhal H, Diefenbach MA.
Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis.
Med Decis Making. 2014 Nov 10. pii: 0272989X14558424. [Epub ahead of print]
Abstract | Related citations

TREATMENT



James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Eur Urol. 2014 Oct 6. pii: S0302-2838(14)00969-5. doi: 10.1016/j.eururo.2014.09.032. [Epub ahead of print]
Abstract | Full text | Related citations


Castration-resistant prostate cancer


Satoh T, Uemura H, Tanabe K, Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono S, Akaza H.
A phase 2 study of abiraterone acetate in japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi: 10.1093/jjco/hyu148. Epub 2014 Oct 1.
Abstract | Full text | Related citations


Wen SM, Quan CY, Jiang N, Shang ZQ, Niu YJ.
What is the next generation therapeutic strategy for castration-resistant prostate cancer.
Asian J Androl. 2014 Nov 18. doi: 10.4103/1008-682X.143311. [Epub ahead of print]
Abstract | Full text | Related citations


Decision making


Su MZ, Kneebone AB, Woo HH.
Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers?
Expert Rev Anticancer Ther. 2014 Nov;14(11):1265-70. doi: 10.1586/14737140.2014.972381.
Abstract | Full text | Related citations